Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
Hs 578T Cabozantinib
0.31623
VEGFR2/MET
RTK
 0.9045 0.01765
Hs 578T Cabozantinib
3.1623
VEGFR2/MET
RTK
 0.8488 0.03305
Hs 578T Cabozantinib
1.0
VEGFR2/MET
RTK
 0.8396 0.02688
SK-BR-3 Cabozantinib
0.31623
VEGFR2/MET
RTK
 1.2300 -0.00894
HCC1806 Neratinib
0.1
EGFR/HER2
RTK
 0.7682 0.05014
Hs 578T Neratinib
0.00031623
EGFR/HER2
RTK
 1.0519 0.00196
HCC1806 Tivantinib
0.01
MET
RTK
 1.0496 -0.00152
MCF 10A Ceritinib
0.0031623
ALK
RTK
 1.0028 -0.00071
HCC1806 Neratinib
1.0
EGFR/HER2
RTK
 0.5513 0.07881
MCF 10A Ceritinib
0.1
ALK
RTK
 0.9635 -0.00161
HCC1806 Ceritinib
0.001
ALK
RTK
 1.0121 0.00605
HCC1806 Ceritinib
0.0031623
ALK
RTK
 1.0658 -0.00214
HCC1806 Ceritinib
0.01
ALK
RTK
 1.0487 0.00015
HCC1806 Ceritinib
0.031623
ALK
RTK
 1.0774 -0.00516
HCC1806 Ceritinib
0.1
ALK
RTK
 1.0986 -0.00400
HCC1806 Ceritinib
0.31623
ALK
RTK
 1.1237 -0.00775
HCC1806 Ceritinib
1.0
ALK
RTK
 0.8590 0.02331
HCC1806 Ceritinib
3.1623
ALK
RTK
 0.1763 0.12321
HCC1806 Ceritinib
10.0
ALK
RTK
 -0.4060 0.58043
HCC1806 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0684 0.00476
HCC1806 Neratinib
0.001
EGFR/HER2
RTK
 1.0533 -0.00088
HCC1806 Neratinib
0.0031623
EGFR/HER2
RTK
 1.0102 0.00509
HCC1806 Neratinib
0.01
EGFR/HER2
RTK
 0.9959 0.01677
BT-20 Ceritinib
0.1
ALK
RTK
 1.0073 0.00247
BT-20 Ceritinib
0.031623
ALK
RTK
 1.0677 -0.00061